Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
Filed with ASX · · 3 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Amplia Receives R&D Tax Rebate Totalling $ 2.4 Million
- AACR Ovarian Cancer Conference Presentation
- ATX Quarterly Activities and Cashflow Reports - June 23 Qtr
- Annual Report to Shareholders
- AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
Later from Amplia Therapeutics
- Appendix 4D and Financial Report Half Year ended 30 Sep 23
- Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea
- Amplia Reports First Patient Dosing In Phase 2a Accent Trial
- FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
- Update on ACCENT Trial in Pancreatic Cancer
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics